异动解读 | 特朗普签署迷幻药监管支持行政命令,Definium Therapeutics盘前大涨6.34%

异动解读
Apr 21

Definium Therapeutics(股票代码:DFTX)今日盘前股价大幅上涨6.34%,引起了市场的广泛关注。

消息面上,此次股价异动主要源于行业性的政策利好。据报道,美国总统特朗普签署了一项行政命令,要求卫生监管机构加快对伊博格碱等迷幻药的审查流程,并拨出5000万美元专款用于相关研究。此举被市场解读为政府对迷幻药治疗领域的正式认可与实质性支持,从而提振了投资者信心。

受此消息影响,整个迷幻药开发板块应声上涨。分析人士指出,该行政命令标志着官方支持从“空谈”转向“真实可操作”,获得“突破性疗法”称号的迷幻药未来有望获得优先审查,从而大幅缩短审批时间,为相关公司带来发展机遇。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10